Seres Therapeutics (STU:1S90) OCF Margin %: -3,041.94% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1S90 Seres Therapeutics Inc STU:1S90
25 GF Score
Price €4.05
! 5 Warning Signs
View Full Analysis

What is Seres Therapeutics OCF Margin %?

Seres Therapeutics STU:1S90 -4.71% 25 OCF Margin % is -3,041.94% as of Jun. 2026. GuruFocus rates STU:1S90 with a GF Score™ of 25/100. The stock has 5 warning signs investors should review. Among 957 Biotechnology companies, Seres Therapeutics ranks worse than 87.04% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Seres Therapeutics's Cash Flow from Operations for the three months ended in Jun. 2026 was €-19.44 Mil. Seres Therapeutics's Revenue for the three months ended in Jun. 2026 was €0.64 Mil. Therefore, Seres Therapeutics's OCF Margin % for the quarter that ended in Jun. 2026 was -3,041.94%.

As of today, Seres Therapeutics's current OCF Yield % is -102.06%.

The historical rank and industry rank for Seres Therapeutics's OCF Margin % or its related term are showing as below:

STU:1S90' s OCF Margin % Range Over the Past 10 Years
Min: -281.83   Med: -221.76   Max: 201.79
Current: -2727.73

During the past 13 years, the highest OCF Margin % of Seres Therapeutics was 201.79%. The lowest was -281.83%. And the median was -221.76%.

STU:1S90's OCF Margin % is ranked worse than
87.04% of 957 companies
in the Biotechnology industry
Industry Median: -68.47 vs STU:1S90: -2727.73

Seres Therapeutics OCF Margin % Related Terms

Seres Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Seres Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seres Therapeutics OCF Margin % Chart

Seres Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.61 0.00 0.00 0.00 141.54

Seres Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -1,863.80 -4,564.84 -3,041.94

STU:1S90 vs IBO, TIL, ATYR: OCF Margin % Comparison

For the Biotechnology subindustry, Seres Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seres Therapeutics OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seres Therapeutics's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Seres Therapeutics's OCF Margin % falls into.


STU:1S90
25GF Score
Seres Therapeutics Inc STU:1S90
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seres Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Seres Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=0.954/0.674
=141.54 %

Seres Therapeutics's OCF Margin for the quarter that ended in Jun. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-19.438/0.639
=-3,041.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -3,041.94% mean?
Seres Therapeutics (STU:1S90) has a OCF Margin % of -3,041.94% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Seres Therapeutics and its competitors. According to the industry distribution chart, Seres Therapeutics ranks #833 out of 957 companies in the Biotechnology industry, placing it in the top 87%.
Is Seres Therapeutics' OCF Margin % too high?
Seres Therapeutics' current OCF Margin % is -3,041.94%. Based on the distribution chart, Seres Therapeutics ranks #833 out of 957 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Seres Therapeutics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Seres Therapeutics' OCF Margin % compare to IBO and TIL?
According to the Biotechnology industry distribution chart, Seres Therapeutics ranks #833 out of 957 companies for OCF Margin %. This places Seres Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Seres Therapeutics and its competitors. Seres Therapeutics's current OCF Margin % is -3,041.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seres Therapeutics stock overvalued right now?
Seres Therapeutics (STU:1S90) has a current OCF Margin % of -3,041.94%. The current OCF Margin % is -3,041.94%. Seres Therapeutics' overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Seres Therapeutics (STU:1S90), the current OCF Margin % is -3,041.94% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seres Therapeutics Business Description

Other Exchanges MCRB:USA
Address 101 Cambridgepark Drive, Cambridge, MA, USA, 02140
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
25GF Score

Get the complete analysis for STU:1S90

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.05
Price